AGC Biologics is a global Contract Development and Manufacturing Organization (CDMO) of therapeutic proteins, with a strong commitment to deliver the highest standard of service. Focused on early-phase, the AGC Biologics Berkeley facility operates within the global AGC Biologics integrated platform, with comprehensive support from each individual AGC Biologics site. This strategic structure facilitates transition from early-phase through commercial production, in partnership with a single CDMO. AGC Biologics was formed from a merger between Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company currently employs more than 850 employees spanning three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan [1].
The company has added capacity to its Berkeley, California facility with the addition of a 2000L single-use bioreactor (SUB). The new 2000L SUB underlines AGC Biologics’ strong commitment to substantial and continued growth within each of its six facilities across the globe. The Berkeley, California facility has tripled in capacity over the last three years to meet market demand, and now offers cell culture manufacturing in scales from 100L to 3000L, with both SUBs and stainless steel bioreactors. In addition to cGMP manufacturing, the facility provides skilled cell bank manufacturing and storage.
AGC Biologics has deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for both mammalian and microbial. The company’s integrated services include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression, including the company’s proprietary CHEF1® Expression System for mammalian production.
“We’ve carefully assembled an experienced team that is tuned in to the unique needs of customers within the critical early-phase development stage … We continue to expand capacity and capabilities to meet the diverse requisites within the early-phase manufacturing arena, and we value the opportunity to support companies developing tomorrow’s breakthrough treatments.” – Vy Nguyen, site head of AGC Biologics, Berkeley.
Sources
